Epidermal growth factor-induced nuclear factor κB activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
The epidermal growth factor (EGF) family of receptors (EGFR) is overproduced in estrogen receptor (ER) negative (−) breast cancer cells. An inverse correlation of the level of EGFR and ER is observed between ER− and ER positive (+) breast cancer cells. A comparative study with EGFR-overproducing ER− and low-level producing ER+ breast cancer cells suggests that EGF is a major growth-stimulating factor for ER− cells. An outline of the pathway for the EGF-induced enhanced proliferation of ER− human breast cancer cells is proposed. The transmission of mitogenic signal induced by EGF–EGFR interaction is mediated via activation of nuclear factor κB (NF-κB). The basal level of active NF-κB in ER− cells is elevated by EGF and inhibited by anti-EGFR antibody (EGFR-Ab), thus qualifying EGF as a NF-κB activation factor. NF-κB transactivates the cell-cycle regulatory protein, cyclin D1, which causes increased phosphorylation of retinoblastoma protein, more strongly in ER− cells. An inhibitor of phosphatidylinositol 3 kinase, Ly294–002, blocked this event, suggesting a role of the former in the activation of NF-κB by EGF. Go6976, a well-characterized NF-κB inhibitor, blocked EGF-induced NF-κB activation and up-regulation of cell-cycle regulatory proteins. This low molecular weight compound also caused apoptotic death, predominantly more in ER− cells. Thus Go6976 and similar NF-κB inhibitors are potentially novel low molecular weight therapeutic agents for treatment of ER− breast cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mosmann, T. (1983) · Journal of Immunological Methods · doi:10.1016/0022-1759(83)90303-4 · Cited by 56,104
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Dignam, J. D., Lebovitz, R. M., & Roeder, R. G. (1983) · Nucleic Acids Research · doi:10.1093/nar/11.5.1475 · Cited by 11,260
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
The retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862
G 1 Events and Regulation of Cell Proliferation
Pardee, A. B. (1989) · Science · doi:10.1126/science.2683075 · Cited by 2,182
Self-citationSelective inhibition of protein kinase C isozymes by the indolocarbazole Gö 6976
Martiny-Baron, G., Kazanietz, M. G., Mischak, H., Blumberg, P. M., Kochs, G., Hug, H., Marmé, D., & Schächtele, C. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98335-3 · Cited by 1,565
NF-κB is a target of AKT in anti-apoptotic PDGF signalling
Romashkova, J. A., & Makarov, S. S. (1999) · Nature · doi:10.1038/43474 · Cited by 1,517
A Restriction Point for Control of Normal Animal Cell Proliferation
Pardee, A. B. (1974) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.71.4.1286 · Cited by 1,415
Self-citationNF-κB Controls Cell Growth and Differentiation through Transcriptional Regulation of Cyclin D1
Guttridge, D. C., Albanese, C., Reuther, J. Y., Pestell, R. G., & Baldwin, A. S. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.8.5785 · Cited by 1,312
Cited by
Activators and Target Genes of Rel/NF-кB Transcription Factors: From Bench to Bedside
Loop, T., & Pahl, H. L. (2003) · Nuclear Factor кB · doi:10.1007/978-94-010-0163-2_1 · Cited by 3,169
Epidermal growth factor receptor (EGFR) signaling in cancer
Normanno, N., De Luca, A., Bianco, C., Strizzi, L., Mancino, M., Maiello, M. R., Carotenuto, A., De Feo, G., Caponigro, F., & Salomon, D. S. (2006) · Gene · doi:10.1016/j.gene.2005.10.018 · Cited by 2,038
Aggarwal, B. B. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.09.003 · Cited by 1,574
Aggarwal, B. B., Vijayalekshmi, R. V., & Sung, B. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0149 · Cited by 795
Prenzel, N., Fischer, O. M., Streit, S., Hart, S., & Ullrich, A. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080011 · Cited by 673
Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression
Bassères, D. S., & Baldwin, A. S. (2006) · Oncogene · doi:10.1038/sj.onc.1209942 · Cited by 667
BRCA1 and BRCA2 and the genetics of breast and ovarian cancer
Welcsh, P. L. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.7.705 · Cited by 648
ErbB Receptors: Directing Key Signaling Networks Throughout Life
Holbro, T., & Hynes, N. E. (2004) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.44.101802.121440 · Cited by 640
Helbig, G., Christopherson, K. W., Bhat-Nakshatri, P., Kumar, S., Kishimoto, H., Miller, K. D., Broxmeyer, H. E., & Nakshatri, H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300609200 · Cited by 639
Cell Type-Specific Roles of NF-κB Linking Inflammation and Thrombosis
Mussbacher, M., Salzmann, M., Brostjan, C., Hoesel, B., Schoergenhofer, C., Datler, H., Hohensinner, P., Basílio, J., Petzelbauer, P., Assinger, A., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00085 · Cited by 596
Chua, H. L., Bhat-Nakshatri, P., Clare, S. E., Morimiya, A., Badve, S., & Nakshatri, H. (2007) · Oncogene · doi:10.1038/sj.onc.1209808 · Cited by 596
Aggarwal, B. B., Shishodia, S., Takada, Y., Banerjee, S., Newman, R. A., Bueso-Ramos, C. E., & Price, J. E. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1192 · Cited by 584
NF-κB in inflammation and cancer
Mao, H., Zhao, X., & Sun, S.-C. (2025) · Cellular & Molecular Immunology · doi:10.1038/s41423-025-01310-w · Cited by 489
Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling
Clarke, R., Liu, M. C., Bouker, K. B., Gu, Z., Lee, R. Y., Zhu, Y., Skaar, T. C., Gomez, B., O'Brien, K., Wang, Y., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206937 · Cited by 478
New Insights into the Role of Nuclear Factor-κB in Cell Growth Regulation
Chen, F., Castranova, V., & Shi, X. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61708-7 · Cited by 473
NF-κB activation in human breast cancer specimens and its role in cell proliferation and apoptosis
Biswas, D. K., Shi, Q., Baily, S., Strickland, I., Ghosh, S., Pardee, A. B., & Iglehart, J. D. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403621101 · Cited by 447
Self-citationNuclear Factor-κB Activation: From Bench to Bedside
Sethi, G., Sung, B., & Aggarwal, B. B. (2008) · Experimental Biology and Medicine · doi:10.3181/0707-mr-196 · Cited by 417
NF-κB and IKK as therapeutic targets in cancer
Kim, H. J., Hawke, N., & Baldwin, A. S. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401877 · Cited by 391
Transcription factor cross-talk: the estrogen receptor and NF-κB
Kalaitzidis, D., & Gilmore, T. D. (2005) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2005.01.004 · Cited by 388
Chinnaiyan, P., Huang, S., Vallabhaneni, G., Armstrong, E., Varambally, S., Tomlins, S. A., Chinnaiyan, A. M., & Harari, P. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3547 · Cited by 386
Nuclear Factor-κB in Development, Prevention, and Therapy of Cancer
Van Waes, C. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2221 · Cited by 292
Targeting the NFκB Signaling Pathways for Breast Cancer Prevention and Therapy
Wang, W., Nag, S., & Zhang, R. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666141106124315 · Cited by 282
The role of IKK in constitutive activation of NF-κB transcription factor in prostate carcinoma cells
Gasparian, A. V., Yao, Y. J., Kowalczyk, D., Lyakh, L. A., Karseladze, A., Slaga, T. J., & Budunova, I. V. (2002) · Journal of Cell Science · doi:10.1242/jcs.115.1.141 · Cited by 275
Aggarwal, S., Takada, Y., Singh, S., Myers, J. N., & Aggarwal, B. B. (2004) · International Journal of Cancer · doi:10.1002/ijc.20333 · Cited by 274
Protein kinase C (PKC) family in cancer progression
Koivunen, J., Aaltonen, V., & Peltonen, J. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.03.033 · Cited by 261
Engineering Nanocomposite Materials for Cancer Therapy
Minelli, C., Lowe, S. B., & Stevens, M. M. (2010) · Small · doi:10.1002/smll.201000523 · Cited by 255
From Calcium to NF-κB Signaling Pathways in Neurons
Lilienbaum, A., & Israël, A. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.8.2680-2698.2003 · Cited by 253
Multitargeted therapy of cancer by ellagitannins
Heber, D. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.03.043 · Cited by 227
EGFR and NF-κB: partners in cancer
Shostak, K., & Chariot, A. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.04.001 · Cited by 220
Gee, J. M., Robertson, J. F., Gutteridge, E., Ellis, I. O., Pinder, S. E., Rubini, M., & Nicholson, R. I. (2005) · Endocrine-Related Cancer · doi:10.1677/erc.1.01005 · Cited by 209
“Certainly, the ER phenotype in vitro commonly exhibits marked EGFR overexpression coupled with hyperactivation of downstream MAPK, and in some ER cell lines the EGFR signalling pathway is growth contributory (Biswas et al. 2000).”
BackgroundHypoxia and Inflammation in Cancer, Focus on HIF and NF-κB
D’Ignazio, L., Batie, M., & Rocha, S. (2017) · Biomedicines · doi:10.3390/biomedicines5020021 · Cited by 205
“There is also evidence of Epidermal Growth Factor (EGF) signalling enhancing NF-κB activity in breast cancer [150].”
BackgroundThe NF-κB/IκB signaling system: A molecular target in breast cancer therapy
Wu, J. T., & Kral, J. G. (2005) · Journal of Surgical Research · doi:10.1016/j.jss.2004.06.006 · Cited by 205
Nuclear factor‐κB (nf‐κB) is frequently expressed in lung cancer and preneoplastic lesions
Tang, X., Liu, D., Shishodia, S., Ozburn, N., Behrens, C., Lee, J. J., Hong, W. K., Aggarwal, B. B., & Wistuba, I. I. (2006) · Cancer · doi:10.1002/cncr.22315 · Cited by 190
Fruit and vegetable intake and risk of breast cancer by hormone receptor status
Jung, S., Spiegelman, D., Baglietto, L., Bernstein, L., Boggs, D. A., van den Brandt, P. A., Buring, J. E., Cerhan, J. R., Gaudet, M. M., Giles, G. G., et al. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs635 · Cited by 183
EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway
Bonavia, R., Inda, M. M., Vandenberg, S., Cheng, S.-Y., Nagane, M., Hadwiger, P., Tan, P., Sah, D. W. Y., Cavenee, W. K., & Furnari, F. B. (2012) · Oncogene · doi:10.1038/onc.2011.563 · Cited by 170
“…it was suggested that EGFR induces NF-kB activation, and this pathway is important in the maintenance of tumors bearing amplification/activation of EGFR or others members of the ErbB family (Biswas et al., 2000), the molecular mechanisms linking EGFR with NF-kB are not completely understood.”
Payne, C. M., Weber, C., Crowley-Skillicorn, C., Dvorak, K., Bernstein, H., Bernstein, C., Holubec, H., Dvorakova, B., & Garewal, H. (2007) · Carcinogenesis · doi:10.1093/carcin/bgl139 · Cited by 166
Wang, Y., Liu, L., Moore, D. J., Shen, X., Peek, R. M., Acra, S. A., Li, H., Ren, X., Polk, D. B., & Yan, F. (2017) · Mucosal Immunology · doi:10.1038/mi.2016.57 · Cited by 149
Development of Dual Inhibitors Targeting Epidermal Growth Factor Receptor in Cancer Therapy
Tan, L., Zhang, J., Wang, Y., Wang, X., Wang, Y., Zhang, Z., Shuai, W., Wang, G., Chen, J., Wang, C., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01714 · Cited by 88
Metadata
- Authors
- Biswas, D. K., Cruz, A. P., Gansberger, E., & Pardee, A. B.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2000-07-18
- Volume
- 97
- Issue
- 15
- Pages
- 8542-8547
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2026863172
- Cited by
- 351
- References
- 45
- FWCI
- 8.66
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.